<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586091</url>
  </required_header>
  <id_info>
    <org_study_id>2010-022747-38</org_study_id>
    <nct_id>NCT01586091</nct_id>
  </id_info>
  <brief_title>Safety Study of Levocetirizine and Fexofenadine</brief_title>
  <acronym>LAWAF</acronym>
  <official_title>Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Study is to comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once
      daily with Fexofenadine 60 mg twice daily in the histamine induced wheal, flare and itch
      Response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled study with intra-individual
      comparison of the histamine induced wheal and flare reaction. In September 2009, Fexofenadine
      was approved as an antihistamine against allergies in Japan and it is currently used widely.
      It has been approved in 120 countries, including the US, UK, France and Germany [11]. In
      Europe and the United States, fexofenadine is marketed at 120 mg once daily for allergic
      rhinitis and 180mg once daily for urticaria. In Japan, fexofenadine is marketed at 60 mg
      twice daily for both conditions. But is this dosage regimen as effective as levocetirizine, 5
      mg once daily? The above described study from Takahashi et al, comparing 60 mg twice daily
      versus cetirizine 10 mg once daily suggests that it is not [4]. The aim of the study is to
      compare the efficacy and consistency of action of levocetirizine 5 mg once daily with
      fexofenadine 60 mg twice daily over a 24 hour period in the histamine induced wheal, flare
      and itch response. Furthermore, we would like to investigate whether a different between
      Japanese and Caucasian exists or not. Each volunteer will receive the study medication at
      time point 0 and 12 hour later. Skin Prick Test (SPT) will be performed in each volunteer
      using histamine (10 mg/ml), 15 minutes before drug admission (baseline) and at 0.5, 1, 2, 3,
      4, 6, 8, 10, 12 and 24 hours afterwards. Volumetric optical scanning system and infrared
      camera will be used for objective evaluation of the wheal- and flare reduction. Additionally,
      measurement of the erythema diameter with a transparent ruler will be performed. The
      subjective intensity of itching will be assessed using a Visual Analogue Scale (VAS). To
      relate the pharmacokinetics of the drugs to their pharmacodynamics, blood samples for assay
      of drug concentrations will be taken at baseline and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24
      hours later. Subjects will undergo the same procedure on three separate occasions to receive
      each treatment option. The options are: placebo at time 0 hours + placebo at 12 hours,
      Levocetirizine 5mg at time 0 hours + placebo at 12 hours or fexofenadine 60mg at time 0 hours
      + fexofenadine 60mg at 12 hours. There will be a washout period of at least 6 days between
      the treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pruritus as Assessed by the VAS Score</measure>
    <time_frame>up to 10 minutes after skin prick test performed 24 hours after drug administration</time_frame>
    <description>We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a &quot;0&quot; and &quot;100&quot; at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flaire Diameter (mm)</measure>
    <time_frame>24 hours per treatment</time_frame>
    <description>Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wheal Volume (cm3)</measure>
    <time_frame>24 hours per treatment</time_frame>
    <description>Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pruritus</condition>
  <condition>Chronic Urticaria</condition>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo per os at time 0 hours + placebo per os at 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levocetirizin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levocetirizin 5mg at time 0 and placebo per os at 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fexofenadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine Oral Tablet</intervention_name>
    <arm_group_label>Levocetirizin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine 60 Mg Oral Tablet</intervention_name>
    <arm_group_label>Fexofenadine</arm_group_label>
    <other_name>Telfast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <arm_group_label>Levocetirizin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lichtenstein</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eighteen (18) healthy male volunteers, including at least 6 persons of Japanese origin,
        will be recruited for this study

        Exclusion Criteria:

          -  None of the subjects will have taken oral antihistamines, antidepressants,
             antipsychotics or corticosteroids or applied topical antihistamines, corticosteroids
             or mast cell stabilizers to the skin for 2 weeks prior to testing.

          -  No subject shall perform physical exercise for 4 hours prior to the skin prick
             testing.

          -  Especially, Bronchial asthma, anaphylactic reactions in the history, use of
             beta-blockers, skin diseases in the test field are exclusion criteria.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Universitätsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Berlin Charité, Department of Dermatology and Allergy</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <results_first_submitted>January 29, 2016</results_first_submitted>
  <results_first_submitted_qc>September 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2019</results_first_posted>
  <last_update_submitted>September 15, 2019</last_update_submitted>
  <last_update_submitted_qc>September 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Martin Metz</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be available.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Day 1</title>
          <description>Intake of Placebo- Fexofenadine 6 mg - Levocetirizin 5 mg</description>
        </group>
        <group group_id="P2">
          <title>Day 2</title>
          <description>Intake of Fexofenadine 6 mg - Levocetirizin 5 mg - Placebo</description>
        </group>
        <group group_id="P3">
          <title>Day 3</title>
          <description>Intake of Placebo- Levocetirizin 5 mg- Fexofenadine 60</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6">9 Caucasian and 9 Asian participants, each received Levocetiricine, fexofenadine and Placebo.</participants>
                <participants group_id="P2" count="6">9 Caucasian and 9 Asian participants, each received Levocetiricine, fexofenadine and Placebo.</participants>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6">9 Caucasian and 9 Asian participants, each received Levocetiricine, fexofenadine and Placebo.</participants>
                <participants group_id="P2" count="6">9 Caucasian and 9 Asian participants, each received Levocetiricine, fexofenadine and Placebo.</participants>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Day 2</title>
          <description>Intake on 0 hours and 12 hours Intake Levocetirizn</description>
        </group>
        <group group_id="B2">
          <title>Day 3</title>
          <description>Intake on 0 hours and 12 hours Intake Fexofenadine</description>
        </group>
        <group group_id="B3">
          <title>Day 1</title>
          <description>Intake on 0 hours and 12 hours Intake Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>A total of 9 Patients (includes Asian and Caucasian) per Arm/Group were analysed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pruritus as Assessed by the VAS Score</title>
        <description>We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a &quot;0&quot; and &quot;100&quot; at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point.</description>
        <time_frame>up to 10 minutes after skin prick test performed 24 hours after drug administration</time_frame>
        <population>Please see Outcome Measure Description. Itch was measured using a 10 point VAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Levocetirizin</title>
            <description>5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Fexofenadine</title>
            <description>60 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo as comparison to Levocetirizin</description>
          </group>
        </group_list>
        <measure>
          <title>Pruritus as Assessed by the VAS Score</title>
          <description>We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a &quot;0&quot; and &quot;100&quot; at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point.</description>
          <population>Please see Outcome Measure Description. Itch was measured using a 10 point VAS.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="16.4"/>
                    <measurement group_id="O2" value="25.4" spread="35.3"/>
                    <measurement group_id="O3" value="46.0" spread="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flaire Diameter (mm)</title>
        <description>Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this.</description>
        <time_frame>24 hours per treatment</time_frame>
        <population>Please see Outcome measure description. Flair Diameter was measured in mm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo as comparison to Levocetirizin</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizin</title>
            <description>5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Fexofenadine</title>
            <description>60 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Flaire Diameter (mm)</title>
          <description>Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this.</description>
          <population>Please see Outcome measure description. Flair Diameter was measured in mm.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" spread="24.8"/>
                    <measurement group_id="O2" value="20.4" spread="10.0"/>
                    <measurement group_id="O3" value="39.9" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Wheal Volume (cm3)</title>
        <description>Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany).</description>
        <time_frame>24 hours per treatment</time_frame>
        <population>Please see Outcome Measure Description. Wheal volume was measured in cm3. The units of measure are provided in the report of the this study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo as comparison to Levocetirizin</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizin</title>
            <description>5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Fexofenadine</title>
            <description>60 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Wheal Volume (cm3)</title>
          <description>Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany).</description>
          <population>Please see Outcome Measure Description. Wheal volume was measured in cm3. The units of measure are provided in the report of the this study protocol.</population>
          <units>cm3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.6" spread="50.9"/>
                    <measurement group_id="O2" value="35.2" spread="13.5"/>
                    <measurement group_id="O3" value="106.3" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected on the following time points: 0 (baseline), 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Levocetirizine</title>
          <description>5 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Fexofenadine</title>
          <description>60 mg twice daily, oral</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo against Levocetirzine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bacterial inflammation of the finger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain at the puncture site of the intravenous catheter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>pain in the knee joint</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Marcus Maurer</name_or_title>
      <organization>University of Charité Berlin; Dpt. of Dermatology and Allergy</organization>
      <phone>+49 30 450 518 043</phone>
      <email>marcus.maurer@charite.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

